Pfizer keeps coronavirus sales forecast unchanged as pandemic curbs ease
The company's reluctance to lift that forecast could signal a dearth of new sales contracts for the drug during the first quarter.;
New Delhi: Pfizer Inc maintained sales forecasts for its pandemic products on Tuesday after a series of hikes to revenue projections for its COVID-19 vaccine last year, in a sign that dizzying growth has slowed.
Several countries have eased pandemic restrictions, relaxing rules on masking and quarantines, even as cases rise in some regions.
The company said it expects $22 billion in sales from its COVID treatment Paxlovid this year, compared with analysts' average expectation of $26.1 billion, according to Refinitiv.
Pfizer had previously said its $22 billion forecast for sales of the pills only represents a fraction of the 120 million courses the company is able to manufacture this year.
The company's reluctance to lift that forecast could signal a dearth of new sales contracts for the drug during the first quarter.
Pfizer also reiterated its 2022 forecast for $32 billion in sales from the COVID vaccine it developed with BioNTech SE. Pfizer had raised its COVID-19 vaccine sales forecast every quarter in 2021.
Read also: Pfizer to launch global drug development centre at IIT Madras Research Park
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.